-
Older women taking combination hormone therapy had dementia twice as often as women not taking the therapy, according to a recently published study.
-
The U.S. Food and Drug Administration (FDA) is warning pharmacists and consumers to beware of counterfeit atorvastatin calcium (Lipitor).
-
The U.S. Supreme Court has ruled that Maine can continue with its efforts to implement its Maine Rx program, which was designed primarily to provide discounted prescription drugs to Maines uninsured residents.
-
The FDA has announced two measures to inform the public about the status of manufacturers commitments to carry out further clinical studies following the FDAs approval of certain drugs and biological products.
-
Due to manufacturing problems, the U.S. Food and Drug Administration (FDA) took urokinase (Abbokinase) off the market in December 1998. During inspection of the manufacturing facility in October and November of 1998, urokinase production was found to differ from Good Manufacturing Practice regulations.
-
-
If youre having trouble retaining and recruiting ED nurses, it may be time to closely examine your violence prevention strategies. The University of Alberta (Canada) Faculty of Nursing surveyed more than 9,000 nurses.
-
Purpose: To establish staff guidelines for the management of patients in need of a psychiatric assessment that will help ensure the safety of patients and staff in the Emergency Department.
-
Purpose: To maintain safety and security for all individuals in the hospital environment, in the least restrictive and safest way during an episode of escalation.
-
Editors note: This column is part of an ongoing series that will address reader questions about the Emergency Medical Treatment and Labor Act (EMTALA).
